The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells
Abstract
Development of multidrug resistance (MDR) against a variety of conventional and novel chemotherapeutic agents is a significant challenge in effective cancer therapy. Over the last several years, we have focused on a multimodal therapeutic strategy to overcome tumor MDR by enhancing the delivery efficiency to the tumor mass and lowering the apoptotic threshold by modulation of the intracellular signaling mechanisms. In this study, we have examined augmentation of therapeutic efficacy upon coadministration of paclitaxel (PTX) and curcumin (CUR), an inhibitor of nuclear factor kappa B (NFkappaB) as well as a potent down-regulator of ABC transporters, in wild-type SKOV3 and drug resistant SKOV3(TR) human ovarian adenocarcinoma cells. PTX and CUR were encapsulated in flaxseed oil containing nanoemulsion formulations. The results showed that the encapsulated drugs were effectively delivered intracellular in both SKOV3 and SKOV3(TR) cells. CUR administration was shown to inhibit NFkappaB activity and down regulate P-glycoprotein expression in resistant cells. Combination PTX and CUR therapy, especially when administered in the nanoemulsion formulations, was very effective in enhancing the cytotoxicity in wild-type and resistant cells by promoting the apoptotic response. Overall, this cotherapy strategy has significant promise in the clinical management of refractory diseases, especially in ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
Omega-3 fatty acids as cancer chemopreventive agents
Rose, D. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00026-1 · Cited by 625
Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., Bueso-Ramos, C. E., & Price, J. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1192 · Cited by 584
Chou, T.-C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1517 · Cited by 524
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Self-citationGlutathione S-transferases and drug resistance
(1991) · International Journal of Biochemistry · doi:10.1016/0020-711x(91)90023-g · Cited by 305
Krishnamachary, N., & M S Center (1993) · PubMed · Cited by 296
Engineering of nanoemulsions for drug delivery
Sarker, D. (2005) · Current Drug Delivery · doi:10.2174/156720105774370267 · Cited by 268
Vyas, T. K., Shahiwala, A., & Amiji, M. M. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.016 · Cited by 264
Self-citationDeffie, A. M., Batra, J. K., & Goldenberg, G. J. (1989) · PubMed · Cited by 261
Chearwae, W., Anuchapreeda, S., Nandigama, K., Ambudkar, S. V., & Limtrakul, P. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.009 · Cited by 229
van Vlerken, L. E., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1648 · Cited by 214
Self-citationLimtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C., & Ambudkar, S. V. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9302-8 · Cited by 208
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205
Multidrug Resistance and Cancer: The Role of the Human ABC Transporter ABCG2
Ejendal, K. F., & Hrycyna, C. A. (2002) · Current Protein & Peptide Science · doi:10.2174/1389203023380521 · Cited by 161
van Vlerken, L. E., Duan, Z., Little, S. R., Seiden, M. V., & Amiji, M. M. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800030k · Cited by 144
Self-citationImproved Oral Delivery of Paclitaxel Following Administration in Nanoemulsion Formulations
Tiwari, S. B., & Amiji, M. M. (2006) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2006.440 · Cited by 139
Self-citationDesai, A. R., Vyas, T. K., & Amiji, M. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21182 · Cited by 128
Self-citationDevalapally, H., Duan, Z., Seiden, M. V., & Amiji, M. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4973 · Cited by 121
Self-citationDevalapally, H., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22886 · Cited by 110
Self-citationChearwae, W., Wu, C., Chu, H., Lee, T. R., Ambudkar, S. V., & Limtrakul, P. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0052-1 · Cited by 107
Possible Anaphylaxis after Propofol in a Child with Food Allergy
Hofer, K. N., McCarthy, M., Buck, M., & Hendrick, A. (2003) · The Annals of Pharmacotherapy · doi:10.1345/aph.1c227 · Cited by 82
Molinari, A., Calcabrini, A., Meschini, S., Stringaro, A., Crateri, P., Toccacieli, L., Marra, M., Colone, M., Cianfriglia, M., & Arancia, G. (2002) · Current Protein and Peptide Science · doi:10.2174/1389203023380413 · Cited by 78
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion
Ganta, S., Paxton, J. W., Baguley, B. C., et al. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.027 · Cited by 68
Self-citationMultidrug Resistance in the Laboratory and Clinic
Bellamy, W. T., & Dalton, W. S. (1994) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)60332-7 · Cited by 64
Pharmacokinetics and Tissue Distribution of Etoposide Delivered in Parenteral Emulsion
Patlolla, R. R., & Vobalaboina, V. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20249 · Cited by 59
Tiwari, S. B., Tan, Y.-M., & Amiji, M. M. (2006) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2006.038 · Cited by 55
Self-citation
Cited by
Nanoemulsion: Concepts, development and applications in drug delivery
Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.008 · Cited by 1,358
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Another group encapsulated curcumin, known as P-glycoprotein pump inhibitor, and Paclitaxel in a nanoemulsion of flaxseed oil to effectively treat wild-type and drug resistant SKOV3 ovarian tumor cells [115].”
BackgroundUnderstanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Self-citationKlang, V., Matsko, N. B., Valenta, C., & Hofer, F. (2012) · Micron · doi:10.1016/j.micron.2011.07.014 · Cited by 329
Metadata
- Authors
- Ganta, S., & Amiji, M.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-04-01
- Volume
- 6
- Issue
- 3
- Pages
- 928-939
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2087266891
- Cited by
- 490
- References
- 31
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
